Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile

References

• Park EJ, Amatya S, Kim MS, et al. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res. 2013;36(6):651–659. doi:10.1007/s12272-013-0105-723543652
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Bertolini F, Del Giovane C, et al. Maintenance treatment with long-acting injectable antipsychotics for people with non-affective psychoses: a network meta-analysis. Am J Psychiatry. 2021;178(5):appiajp202020071120. doi:10.1176/appi.ajp.2020.20071120
   Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective Cohort studies. Schizophr Bull. 2018;44(3):603–619. doi:10.1093/schbul/sbx09029868849
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74:686–693. doi:10.1001/jamapsychiatry.2017.132228593216
   PubMed Web of Science ®Google Scholar
• Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19:3–5. doi:10.1017/S109285291300101624512639
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754–768. doi:10.18553/jmcp.2015.21.9.75426308223
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull. 2007;33(6):1379–1387. doi:10.1093/schbul/sbm03317470444
   PubMed Web of Science ®Google Scholar
• Barbui C, Bertolini F, Bartoli F, et al. Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study. Ther Adv Psychopharmacol. 2020;10:2045125320978102. doi:10.1177/204512532097810233489087
   PubMed Web of Science ®Google Scholar
• Heres S, Hamann J, Kissling W. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006;67(12):1948–1953. doi:10.4088/JCP.v67n121617194274
   PubMed Web of Science ®Google Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62. doi:10.2147/PROM.S4273525061342
   PubMedGoogle Scholar
• Misawa F, Kishimoto T, Hagi K, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2–3):220–230. doi:10.1016/j.schres.2016.07.01827499361
   PubMed Web of Science ®Google Scholar
• Zolezzi M. Long-acting injectable antipsychotics: review and recent developments. Neurosciences. 2005;10(2):126–131.22473224
   PubMedGoogle Scholar
• Wynaden D, Landsborough I, McGowan S, et al. Best practice guidelines for the administration of intramuscular injections in the mental health setting. Int J Ment Health Nurs. 2006;15:195–200. doi:10.1111/j.1447-0349.2006.00423.x16916413
   PubMed Web of Science ®Google Scholar
• Hirano K, Yamada H. Studies on the absorption of practically water-insoluble drugs following injection. IV. An approach for predicting relative intramuscular absorption rates of a drug in oily solution, aqueous suspension and aqueous surfactant solution in rats. Chem Pharm Bull. 1981;29:1410–1415. doi:10.1248/cpb.29.1410
   Web of Science ®Google Scholar
• Hopkins U, Arias CY. Large-volume IM injections: a review of best practices. Oncol Nurs Advisor. 2013;4:32–37.
   Google Scholar
• Critical Appraisal Skills Programme (CASP). CASP systematic review checklist. [Internet]. Available from: http://www.casp-uk.net/casp-tools-checklists. Accessed 413, 2021.
   Google Scholar
• Hay J. Complications at site of injection of depot neuroleptics. BMJ. 1995;311(7002):421. doi:10.1136/bmj.311.7002.4217640587
   PubMed Web of Science ®Google Scholar
• Jones J, Day J, Taylor J, Thomas C. Investigation of depot neuroleptic injection site reactions. Psychiatr Bull. 1998;22(10):605–607. doi:10.1192/pb.22.10.605
   Google Scholar
• Lindenmayer J, Jarboe K, Bossie C, et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol. 2005;20(4):213–221. doi:10.1097/00004850-200507000-0000415933482
   PubMed Web of Science ®Google Scholar
• Nasrallah H, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate: a long-acting injectable antipsychotic in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072–2082. doi:10.1038/npp.2010.7920555312
   PubMed Web of Science ®Google Scholar
• Quiroz J, Rusch S, Thyssen A, et al. Deltoid injections of risperidone long-acting injectable in patients with schizophrenia. Innov Clin Neurosci. 2011;8(6):20–28.
   Google Scholar
• Kane J, Sanchez R, Perry P, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia. J Clin Psychiatry. 2012;73(05):617–624. doi:10.4088/JCP.11m0753022697189
   PubMed Web of Science ®Google Scholar
• Atkins S, Detke H, McDonnell D, et al. A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection. BMC Psychiatry. 2014;14:7. doi:10.1186/1471-244X-14-724423017
   PubMed Web of Science ®Google Scholar
• Kisely S, Sawyer E, Robinson G, Siskind D. A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome. Schizophr Res. 2019;166(1–3):178–186. doi:10.1016/j.schres.2015.04.028
   Web of Science ®Google Scholar
• Chen W, Lin S. Comparison of subjective experiences and effectiveness of first-generation long-acting injectable antipsychotics and risperidone long-acting injectables in patients with schizophrenia. J Clin Psychopharmacol. 2016;36(5):492–495. doi:10.1097/JCP.000000000000055527580495
   PubMed Web of Science ®Google Scholar
• Kern Sliwa J, Savitz A, Nuamah I, et al. An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate. Perspect Psychiatr Care. 2018;54(4):530–538. doi:10.1111/ppc.1226729446084
   PubMed Web of Science ®Google Scholar
• Ting E, Kamalvand S, Shang D, et al. Does the frequency of administration of long acting injectable antipsychotics impact psychiatric outcomes and adverse effects: a systematic review and meta-analysis. J Psychiatr Res. 2019;109:193–201. doi:10.1016/j.jpsychires.2018.12.00430557706
   PubMed Web of Science ®Google Scholar
• Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171–1180. doi:10.2147/PPA.S5379524265549
   PubMed Web of Science ®Google Scholar
• Lin M, Wo W, Shao P, Chang C. Comparing pain of the first-generation long-acting antipsychotic injections among three different IM techniques. Br J Res. 2017;4(5):33.
   Google Scholar
• Gillespie M, Toner A. The safe administration of long-acting depot antipsychotics. Br J Nurs. 2013;22(8):16–20. doi:10.12968/bjon.2013.22.8.46423299206
   PubMedGoogle Scholar
• Patel MX, De Zoysa N, Baker D, David AS. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs. 2005;12(2):237–244. doi:10.1111/j.1365-2850.2004.00826.x15788043
   PubMedGoogle Scholar
• Taylor M. Deltoid versus gluteal: which intramuscular injection site do mental health patients prefer? (Letter). Aust N Z J Psychiatry. 2020:4867420963737.33028089
   PubMed Web of Science ®Google Scholar
• Geerts Martinez G, Schreiner A. Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses. BMC Psychiatry. 2013;13:58. doi:10.1186/1471-244X-13-5823414331
   PubMed Web of Science ®Google Scholar
• Millet B, Gourevitch R, Levoyer D, et al. Study on how schizophrenic patients perceive treatment with injections in the deltoid muscle. Encephale. 2013;38:97–103. doi:10.1016/j.encep.2011.12.013
   Web of Science ®Google Scholar